I asked ChatGPT to build the perfect Stocks and Shares ISA – and here it is!

Harvey Jones called on artificial intelligence to help him decide where to invest this year’s Stocks and Shares ISA allowance. ChatGPT had this to say.

| More on:
Pink 3D image of the numbers '2025' growing in size

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With a fresh £20,000 Stocks and Shares ISA contribution limit at my disposal this April, I turned to ChatGPT to help me build the perfect FTSE 100 portfolio.

I told the artificial intelligence (AI) chatbot I wanted to balance risk and reward with a mix of growth and income stocks across different sectors. While I’d never treat AI as a stock tipper, I was curious to hear its view.

Its first pick is a share I bought last year (but sometimes wish I hadn’t): spirits giant Diageo. ChatGPT plucked this from the consumer good sector, describing it as a global drinks powerhouse that “offers solid dividends and pricing power in an inflationary environment”.

It admits that the economic slowdown has hit revenues but didn’t mention the thing that really worries me – Gen Z isn’t so fixated on alcohol. That worries me.

A balanced spread from the FTSE 100 

ChatGPT’s second pick is also one I own: insurer and asset manager Legal & General Group, from the financial services sector.

Its shares have idled lately but it does offer a brilliant 8.5% trailing dividend yield. ChatGPT highlights “strong long-term demand for financial planning services” while warning that it’s sensitive to market downturns. I love this one.

AI’s third pick is a share I’ve held in the past, and would like to hold again: Rio Tinto, from the mining and commodities sector. ChatGPT calls it a “reliable dividend payer”, neglecting to mention that it cut shareholder payouts in 2023. To be fair, it does have a 7% trailing yield today.

Rio Tinto shares have been hit by the struggling Chinese economy and volatile commodity prices. But worth considering at a low valuation of just eight times earnings.

The fourth pick is another stock I hold: Scottish Mortgage Investment Trust, from the technology and growth sector. This has been flying lately, although it’s taken a knock from Chinese AI upstart DeepSeek and Donald Trump’s trade wars. But I can’t knock its inclusion as a growth stock, albeit a volatile one.

I also asked ChatGPT to pick one stock it particularly likes. It chose one I don’t hold: pharmaceuticals giant AstraZeneca (LSE: AZN).

AstraZeneca is a top stock, but pricey

Now the UK’s biggest company, my robo-adviser called AstraZeneca the “cornerstone” of its ISA portfolio saying: “It combines resilience with innovation, making it an attractive option for both capital appreciation and stability”.

It said AstraZeneca continues to expand its research and development pipeline and with “blockbuster drugs such as Tagrisso and Imfinzi driving revenues, it’s well-positioned for sustained growth”.

Drug development’s an expensive and uncertain process and my chatty chum warns: “Regulatory approvals and clinical trial outcomes may influence its success”. Meanwhile, patent expirations pose a potential threat to revenue streams, requiring a steady flow of new medicines to offset losses, it adds.

I’m concerned that pharmaceutical companies are in the Trump administration’s firing line, while Astra’s shares aren’t cheap, trading at around 36 times earnings. That’s why I’ve resisted buying. 

But I can’t argue with ChatGPT’s logic. And I won’t dispute its conclusion that “this portfolio offers a blend of stability, income, and growth”.

For investors considering how to build a Stocks and Shares ISA, this wouldn’t be a bad start. But they should research the risks as well as the rewards.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in Diageo Plc, Legal & General Group Plc, and Scottish Mortgage Investment Trust Plc. The Motley Fool UK has recommended AstraZeneca Plc and Diageo Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

2 UK shares that could soar if interest rates sprint lower!

The Bank of England's latest meeting has fed speculation of swingeing interest rate cuts. I think these UK shares could…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

My favourite FTSE dividend stock just jumped 17%! So why am I sad?

This investor has mixed feelings today as a quality dividend stock from the FTSE 250 surged higher in his portfolio.…

Read more »

Investing Articles

Here’s why AstraZeneca stock jumped nearly 6% in the FTSE 100 today

FTSE 100 heavyweight AstraZeneca helped propel the blue-chip index to a record high today. Here's what investors were cheering.

Read more »

Closeup of "interest rates" text in a newspaper
Investing Articles

Interest rates fall again! Here are 3 FTSE dividend growth shares to consider buying

As interest on cash savings becomes increasingly less attractive, Paul Summers has been looking at dividend growth shares for passive…

Read more »

Investing Articles

Up 10% today, I think this FTSE 250 growth share could continue to surge!

Babcock International's flying after upgrading its full-year forecasts. I think the FTSE 250 defence share might just be getting started.

Read more »

Investing Articles

The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's biggest company…

Read more »

Investing Articles

Is this my chance to buy Alphabet shares?

A big step up in AI spending at Google has investors nervous, but has it created an opportunity to buy…

Read more »

Senior woman potting plant in garden at home
Investing Articles

£10k in savings? Here’s how an investor could aim for a monthly second income of £1,200

Mark David Hartley considers how investors could build towards an early retirement plan with a second income from a portfolio…

Read more »